| pubmed-article:8704682 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8704682 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8704682 | lifeskim:mentions | umls-concept:C0006463 | lld:lifeskim |
| pubmed-article:8704682 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:8704682 | lifeskim:mentions | umls-concept:C0376545 | lld:lifeskim |
| pubmed-article:8704682 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:8704682 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8704682 | pubmed:dateCreated | 1996-9-11 | lld:pubmed |
| pubmed-article:8704682 | pubmed:abstractText | Between July 1991 and January 1994, 52 patients with hematologic malignancies underwent BMT using BU/CY2 as conditioning regimen. Median patient age was 38 years. Eleven patients underwent autologous BMT, 22 HLA-identical allogeneic BMT, and 19 patients underwent a MUD or an allogeneic mismatched BMT. GVHD prophylaxis was with cyclosporine/methylprednisone in 26 patients; T cell depletion was used in 15 patients. VOD was observed in 7.5% of patients, IP in 12%, seizures in 4%. The overall incidence of grade II-IV acute GVHD was 35%. Delayed platelet engraftment was observed in seven of 11 patients who underwent autologous BMT. Graft failure was seen in seven of 19 (37%) patients who underwent MUD or allogeneic mismatched BMT. Six of the seven patients received T cell depletion as GVHD prophylaxis. BU/CY2 transplantation from an unrelated or family-mismatched donor with T cell depletion is associated with a high incidence of graft failure. | lld:pubmed |
| pubmed-article:8704682 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8704682 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8704682 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8704682 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8704682 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8704682 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8704682 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8704682 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8704682 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:8704682 | pubmed:author | pubmed-author:ListerJJ | lld:pubmed |
| pubmed-article:8704682 | pubmed:author | pubmed-author:PincusSS | lld:pubmed |
| pubmed-article:8704682 | pubmed:author | pubmed-author:BloomE JEJ | lld:pubmed |
| pubmed-article:8704682 | pubmed:author | pubmed-author:BallE DED | lld:pubmed |
| pubmed-article:8704682 | pubmed:author | pubmed-author:RybkaW BWB | lld:pubmed |
| pubmed-article:8704682 | pubmed:author | pubmed-author:DonnenbergAA | lld:pubmed |
| pubmed-article:8704682 | pubmed:author | pubmed-author:deMagalhaes-S... | lld:pubmed |
| pubmed-article:8704682 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8704682 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:8704682 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8704682 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8704682 | pubmed:pagination | 329-33 | lld:pubmed |
| pubmed-article:8704682 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:meshHeading | pubmed-meshheading:8704682-... | lld:pubmed |
| pubmed-article:8704682 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8704682 | pubmed:articleTitle | Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies. | lld:pubmed |
| pubmed-article:8704682 | pubmed:affiliation | Division of Hematology/Bone Marrow Transplantation, University of Pittsburgh Medical Center, PA 15213-2582, USA. | lld:pubmed |
| pubmed-article:8704682 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8704682 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8704682 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8704682 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8704682 | lld:pubmed |
